Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 174
Filter
1.
J Eur Acad Dermatol Venereol ; 35(2): 396-402, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32564428

ABSTRACT

BACKGROUND: Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant genetic disorder. It is commonly caused by mutations in PTCH1 and chiefly characterized by multiple basal cell carcinomas (BCCs) developing prior to the age of 30 years. In rare cases, NBCCS presents with a late onset of BCC development. OBJECTIVE: To investigate BCC tumorigenesis in two brothers, who showed characteristic features of NBCCS but developed their first BCCs only after the age of 40 years. Two other siblings did not show signs of NBCCS. RESULTS: We obtained blood samples from four siblings and nine BCCs from the two brothers with NBCCS. Whole exome sequencing and RNA sequencing revealed loss of heterozygosity (LOH) of PTCH1 in eight out of nine tumours that consistently involved the same haplotype on chromosome 9. This haplotype contained a germinal splice site mutation in PTCH1 (NM_001083605:exon9:c.763-6C>A). Analysis of germline DNA confirmed segregation of this mutation with the disease. All BCCs harboured additional somatic loss-of-function (LoF) mutations in the remaining PTCH1 allele which are not typically seen in other cases of NBCCS. This suggests a hypomorphic nature of the germinal PTCH1 mutation in this family. Furthermore, all BCCs had a similar tumour mutational burden compared to BCCs of unrelated NBCCS patients while harbouring a higher number of damaging PTCH1 mutations. CONCLUSIONS: Our data suggest that a sequence of three genetic hits leads to the late development of BCCs in two brothers with NBCCS: a hypomorphic germline mutation, followed by somatic LOH and additional mutations that complete PTCH1 inactivation. These genetic events are in line with the late occurrence of the first BCC and with the higher number of damaging PTCH1 mutations compared to usual cases of NBCCS.


Subject(s)
Basal Cell Nevus Syndrome , Carcinoma, Basal Cell , Skin Neoplasms , Adult , Basal Cell Nevus Syndrome/genetics , Carcinoma, Basal Cell/genetics , Genomics , Humans , Male , Patched Receptors , Patched-1 Receptor/genetics , Siblings , Skin Neoplasms/genetics
2.
Br J Dermatol ; 165(5): 966-75, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21711332

ABSTRACT

BACKGROUND: Interleukin (IL)-31 is a novel Th2 T-cell cytokine that induces pruritus and dermatitis in transgenic mice. While enhanced mRNA expression of this cytokine is detected in skin samples of inflammatory skin diseases, the regulation of IL-31 expression is poorly understood. OBJECTIVES: To assess the effects of ultraviolet (UV) B radiation and H2O2 on IL-31 mRNA and protein expression in skin and different peripheral blood mononuclear cells (PBMCs). METHODS: The effects of UVB radiation and H2O2, as a prototypic reactive oxygen species, on IL-31 mRNA and protein expression were analysed in various inflammation-related cells and murine skin tissue. RESULTSTreatment of cells with UVB radiation and H2 O2 strongly induced IL-31 mRNA and protein expression in human PBMCs and in the skin of SKH-1 mice. Following exposure to UVB or H2O2, we observed increased expression of IL-31 mRNA in T cells, monocytes, macrophages, and immature and especially mature dendritic cells. H2O2 treatment but not UVB radiation led to a moderate upregulation of IL-31 mRNA expression in epidermal keratinocytes and dermal fibroblasts. Pretreatment of T lymphocytes with the MAPK p38 inhibitor SB203580 or the MEK1 inhibitor U0126 reduced the stimulatory effect of H2O2. These experiments suggest that p38 is involved in the regulation of IL-31 expression in human skin. CONCLUSIONS: Our studies reveal that UVB and reactive oxygen species stimulate the expression of IL-31 in PBMCs and skin, especially in T cells, monocytes and monocyte-derived dendritic cells.


Subject(s)
Dendritic Cells/radiation effects , Hydrogen Peroxide/pharmacology , Interleukins/metabolism , Leukocytes, Mononuclear/radiation effects , Reactive Oxygen Species/pharmacology , T-Lymphocytes/radiation effects , Animals , Cells, Cultured , Fibroblasts/metabolism , Humans , Keratinocytes/metabolism , Mice , Mice, Hairless , RNA, Messenger/metabolism , Skin/metabolism , Ultraviolet Rays
3.
Curr Med Chem ; 15(22): 2258-64, 2008.
Article in English | MEDLINE | ID: mdl-18781947

ABSTRACT

Scientific interest in defining the human body's ability to limit the effects of administered drugs and xenobiotics dates from the mid-19th century when developing knowledge and techniques in the field of organic chemistry first made such studies possible. The first experimental evidence documenting the existence of cytochrome p450 (CYP) dates to the year 1955, when an enzyme system capable of oxidizing xenobiotic compounds was identified in the endoplasmic reticulum of liver homogenates. From these days on several studies analyzed the expression and function of metabolizing phase I enzymes in liver cells. Due to the unique structural features of human skin, little was known about the expression and function of CYP enzymes in this tissue and their role in uptake, metabolism and elimination of xenobiotics as well as endogenous substrates. Lasting recent years it has become clear that human skin cells express various CYP enzymes, including CYP26AI which is responsible for the metabolism of retinoic acid in skin cells. It has been also shown that CYP enzyme expression patterns are cell type and tissue specific and that in skin cells this differs significantly from its expression in other environmental interfaces such as the liver, lung and gastrointestinal tract. Therefore knowledge of skin-specific CYP expression and function is a prerequisite for pharmacological studies of the skin.


Subject(s)
Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Gene Expression Regulation, Enzymologic , Skin/cytology , Skin/enzymology , Epithelium/enzymology , Epithelium/metabolism , Exons/genetics , Humans , Mouth Mucosa/cytology , Skin/metabolism
4.
Clin Exp Dermatol ; 28(2): 206-10, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12653715

ABSTRACT

Monilethrix is an autosomal dominant hair disorder characterized by a beaded appearance of the hair resulting from periodic thinning of the shaft (MIM 158000). The phenotype shows variable penetrance and results in hair fragility and patchy dystrophic alopecia. Mutations of the helix-encoded region in two hair-specific keratins (hHb1 and hHb6) have been identified as responsible for this disorder. We investigated two unrelated families from Russia and Colombia with monilethrix and found two missense mutations in hHb6. In the Russian family, we found a G to A transition at the first base of codon 402, resulting in a lysine substitution (GAG to AAG), designated E402K. In the Colombian family, affected patients carried a missense mutation of codon 413, involving a transition from G to A causing a lysine substitution (GAG to AAG), designated E413K. These two mutations have been identified in other monilethrix families from Europe. Our findings extend the body of evidence implicating recurrent hHb6 and hHb1 mutations in monilethrix families from around the world.


Subject(s)
Hair Diseases/genetics , Keratins/genetics , Mutation, Missense/genetics , Colombia/ethnology , DNA Mutational Analysis , Female , Glutamic Acid/metabolism , Humans , Lysine/biosynthesis , Male , Pedigree , Russia/ethnology
5.
Clin Exp Dermatol ; 28(1): 80-4, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12558638

ABSTRACT

We report the clinical and molecular findings in a patient with a mild form of recessive dystrophic epidermolysis bullosa and aortic insufficiency. To our knowledge, this is the first report of association between dystrophic epidermolysis bullosa and abnormalities of the aortic valve. Analysis of the COL7A1 gene has revealed two new mutations, a 20-bp duplication and a splice site mutation.


Subject(s)
Aortic Valve Insufficiency/genetics , Collagen Type VII/genetics , Epidermolysis Bullosa Dystrophica/genetics , Adult , Epidermolysis Bullosa Dystrophica/pathology , Genes, Recessive/genetics , Genotype , Humans , Male , Mutation/genetics , Pedigree , Phenotype
6.
Drugs ; 61(8): 1067-88, 2001.
Article in English | MEDLINE | ID: mdl-11465870

ABSTRACT

Epizoonoses such as scabies, lice and cimicosis are common, vexing disorders that occur worldwide. Historically, many treatment modalities have been employed in the management of these disorders, and most of the drugs described in this review are of historical interest and no longer recommended or in widespread use because of their wide spectrum of adverse effects. More recently, reports documenting resistance against various antiectoparasite drugs, complicated and severe courses of the diseases, and adverse effects of drug therapy have prompted the development of new treatment strategies and drugs for optimal disease management. Because the strategies currently recommended for the treatment of ectoparasites differ worldwide, this review proposes a rational approach to selecting the best therapeutic agent by comparing the pharmacokinetics, pharmacodynamics, drug efficacy and adverse effects. A literature search of the currently Internet accessible libraries PubMed, Medline and Ideal library, of citations of articles found there, and from communications with the Federal Institute for Drugs and Medical Devices, Germany, was conducted based on this approach. One major observation of this literature search is that permethrin is the treatment of choice for lice and scabies in the US and in Great Britain, whereas lindane is still recommended for scabies in most other European countries because of its longer-standing record of effectiveness. Although permethrin has not yet been proven to be more effective than lindane in treating infections with these ectoparasites, it currently appears to have the best efficacy versus safety profile of topical treatments for scabies and lice. Ivermectin is a newer oral drug for the treatment of ectoparasites, which has been used with great success in the treatment of onchocercosis and other endoparasites. Although ivermectin appears to be a promising drug, its role in the treatment of ectoparasitic infections will be clarified as more study data become available. Finally, it is important to emphasise the clinical aspects of ectoparasite therapy and that providing the patient with optimal instructions on the use of topical therapeutics is of great importance in avoiding adverse effects and assuring complete removal of the ectoparasite, thereby avoiding the development of drug-resistance.


Subject(s)
Anti-Infective Agents/therapeutic use , Ectoparasitic Infestations/drug therapy , Insecticides/therapeutic use , Administration, Oral , Administration, Topical , Adult , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/pharmacology , Child , Drug Resistance , Humans , Insecticides/administration & dosage , Insecticides/pharmacology , Ivermectin/administration & dosage , Ivermectin/pharmacology , Ivermectin/therapeutic use , Permethrin/administration & dosage , Permethrin/pharmacology , Permethrin/therapeutic use
8.
9.
Biochem Biophys Res Commun ; 280(4): 1042-7, 2001 Feb 02.
Article in English | MEDLINE | ID: mdl-11162632

ABSTRACT

Cyclooxygenase (COX) is the rate-limiting enzyme in the production of prostaglandins from arachidonic acid. This enzyme exists in at least two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed in most tissues and plays various physiological roles. However, COX-2 expression is induced by a variety of agents, which include pro-inflammatory agents and mitogens. Evidence exists to indicate that increased expression of COX-2 occurs in several types of epithelial neoplasms. In this study, we show the effect of chronic exposure of murine skin to carcinogenic UVB on cutaneous COX-2 expression. SKH-1 mice were irradiated with 180 mJ/cm(2) UVB daily for five days a week for periods ranging from 1 to 20 weeks. Nontumor bearing skin areas of irradiated mice, skin of age-matched controls and benign papillomas and malignant tumors were assessed immunohistochemically for COX-2 expression in these mice. No epidermal staining occurred in any of the non-UVB-treated controls throughout the experiment. Epidermal COX-2 expression only occurred in UVB-irradiated mice. After 1 and 5 weeks of irradiation, patchy epidermal staining mostly confined to the granular layer and stratum corneum was observed. At week 9, staining intensity had increased, particularly in the granular layer. At week 13, staining was uniformly seen in all epidermal layers with particular prominence in the basal cell layer underlying areas of visible epidermal hyperplasia. It is of interest that the most intense staining was seen in the perinuclear region of keratinocytes and at the plasma membrane. At week 20, COX-2 staining was predominant in the granular layer, although in some tissue sections, the entire epidermis was positive. In benign papillomas, staining was confined to the superficial layers of the epidermis and in squamous cell carcinomas (SCCs), patchy staining in the granular and spinous layers predominated. In general, COX-2 expression was more intense in well-differentiated SCCs than in papillomas. In summary, our results indicate that COX-2 serves as an early marker of epidermal UVB exposure and its expression increases in benign papillomas and in SCCs. These results suggest that pharmacological intervention using specific COX-2 inhibitors could have anticarcinogenic effects in UVB-induced human skin cancer.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Isoenzymes/biosynthesis , Papilloma/metabolism , Prostaglandin-Endoperoxide Synthases/biosynthesis , Skin Neoplasms/metabolism , Skin/metabolism , Animals , Carcinoma, Squamous Cell/pathology , Cell Differentiation , Cyclooxygenase 2 , Female , Immunohistochemistry , Mice , Neoplasms, Radiation-Induced/metabolism , Neoplasms, Radiation-Induced/prevention & control , Papilloma/pathology , Protein Isoforms , Skin/radiation effects , Skin Neoplasms/pathology , Time Factors , Ultraviolet Rays
10.
Biochem Biophys Res Commun ; 277(1): 107-11, 2000 Oct 14.
Article in English | MEDLINE | ID: mdl-11027648

ABSTRACT

The ultraviolet B (UVB) portion (280-320 nm) of solar radiation is considered to be a major etiologic factor in human skin cancer and is a known cause of extensive DNA damage. In this study, we observed that UVB exposure of immortalized epidermal keratinocytes (HaCat cells) harboring mutant p53 leads to G(2)/M cell cycle arrest in both asynchronously growing and synchronized cells in a dose dependent manner. Following UVB exposure (200 mJ/cm(2)), we observed a threefold increase in G(2)/M population at 6 h, which increased to sixfold. The observed G(2)/M arrest was associated with an increase in cyclin B level whereas cdc2 protein remained unchanged. However, we observed an accumulation of tyrosine 15 hyperphosphorylated cyclin B-cdc2 complex. In addition, we observed an increase in chk1 kinase and a decrease in cdc25C protein levels. Chk1 phosphorylates cdc25C on serine 216 and inactivates it whereas cdc25C dephosphorylates tyrosine 15 phosphate of cdc2 and activates the cdc2-cyclin B complex. Therefore, the increase in chk1 and the decrease in cdc25C both participate in inhibiting the G2/M transition. Our data identifies two upstream targets leading to inhibition of cyclin B-cdc2 complexes, which explain the inhibition in cyclin B-associated cdc2 kinase following UVB exposure. The inactive phosphorylated cdc2-cyclin B complex remains sequestered in cytoplasm and may migrate to the nucleus following activation. Our data also indicate that UVB exerts unique effects in different types of skin keratinocytes having nonfunctional or mutant p53.


Subject(s)
Cell Cycle/radiation effects , Keratinocytes/cytology , Keratinocytes/radiation effects , Mutation/genetics , Tumor Suppressor Protein p53/physiology , CDC2 Protein Kinase/metabolism , Cell Cycle Proteins/metabolism , Cell Line, Transformed , Checkpoint Kinase 1 , Cyclin B/metabolism , Cyclin B1 , Flow Cytometry , G2 Phase/radiation effects , Gene Expression Regulation/radiation effects , Humans , Keratinocytes/enzymology , Keratinocytes/metabolism , Mitosis/radiation effects , Phosphorylation/radiation effects , Protein Kinases/metabolism , Skin , Tumor Suppressor Protein p53/genetics , Ultraviolet Rays , cdc25 Phosphatases/metabolism
11.
J Dermatol ; 27(11): 691-5, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11138532

ABSTRACT

Protection against sun-induced damage leading to photocarcinogenesis in skin is a highly desirable goal. Among various strategies, chemopreventive approaches utilizing non-toxic agents to prevent the occurrence of precancerous lesions or their surrogate markers are potentially attractive. Epidemiological and experimental studies provide evidence that some naturally occurring chemical agents in the human diet can diminish cancer risk. Aside from water, tea is the most common beverage consumed worldwide. Black tea accounts for nearly 80% of total tea production. Black tea and green tea are derived from the same plant, Camelia sinensis. Green tea contains monomeric polyphenols known as flavanols and black tea contains dimeric flavanols and polymeric polyphenols known as theaflavins (TFs) and thearubigins (TRs). Over the past fifteen years our laboratory has been exploring the feasibility of using tea and its constitutents as an approach to skin cancer prevention. We demonstrated that green tea, black tea and constituent polyphenols protect against chemical- and ultraviolet B (UVB)-induced carcinogenesis and reduce the growth of established tumors in skin. We have also shown the efficacy of green and black tea extracts against UVB and psoralen + ultraviolet A (PUVA)-induced early damage in skin. Although PUVA is highly effective in treating certain skin diseases, careful follow-up studies of cohorts of patients have shown that similar to UVB, PUVA treatment increases the risk for cutaneous squamous cell carcinoma and melanoma. We have found that oral administration of a standardized green tea extract (SGTE) prior to and during treatment of SKH-1 mice diminished PUVA-induced skin hyperplasia and hyperkeratosis. SGTE-treatment also inhibited PUVA-induced accumulation of c-fos and p53 proteins and epithelial hyperproliferation. Both topical application and oral administration of SGTE after PUVA-treatment reduced skin inflammation and cell hyperproliferation. Topical application of SGTE to human skin prior to PUVA-treatment inhibited the delayed skin inflammatory response. Similarly, oral and topical administration of standardized black tea extract (SBTE) and its two major polyphenolic sub-fractions protect against UVB-induced erythema in SKH-1 mice. Furthermore, topical application of tea extracts to human volunteers protects against UVB-induced erythema. In summary, these studies indicate that tea extracts are effective in reducing UVB- and PUVA-mediated DNA damage, expression of early response genes and early inflammatory changes in skin. These studies verify a conceptual rationale for employing naturally occurring dietary constitutents as an approach to cancer chemoprevention.


Subject(s)
Carcinoma, Basal Cell/prevention & control , Carcinoma, Squamous Cell/prevention & control , Flavonoids , Phenols/therapeutic use , Phytotherapy , Polymers/therapeutic use , Skin Neoplasms/prevention & control , Tea/therapeutic use , Animals , Chemoprevention , Humans , Mice , Plant Extracts/therapeutic use , Polyphenols
12.
J Invest Dermatol ; 113(6): 1070-5, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10594754

ABSTRACT

The use of psoralens combined with exposure to ultraviolet A radiation is a major form of treatment for psoriasis and a number of other common skin diseases. Although psoralen plus ultraviolet A treatment is highly effective, careful follow-up cohort studies have shown that it greatly increases risk for the development of cutaneous squamous cell carcinoma and melanoma. Strategies to reduce the risk of cancer development in psoralen plus ultraviolet A-treated populations are highly desirable. In prior studies, we demonstrated that green tea and constituent polyphenols protect against ultraviolet B-induced carcinogenesis and reduce the growth rate of established tumors in skin. In this study, we show that pre- and post-treatment with standardized green tea extract in psoralen plus ultraviolet A treatment populations abrogates the psoralen plus ultraviolet A-induced photochemical damage to skin. Intact mouse and human skin and reconstituted human skin were employed to assess the effect of both topical and oral administration of standardized green tea extract against psoralen plus ultraviolet A-induced photodamage. Oral administration of standardized green tea extract prior to and during multiple psoralen plus ultraviolet A treatments reduced hyperplasia and hyperkeratosis in murine skin. Standardized green tea extract treatment also inhibited accumulation of c-fos and p53 protein induction following a single exposure to psoralen plus ultraviolet A. c-fos and p53 positive cells in psoralen plus ultraviolet A-treated skin were found to be increased by 55.4 +/- 13. 6% and 62.3 +/- 10.5%, respectively, compared with saline-treated unexposed control skin. Oral administration of 0.4 or 0.8% standardized green tea extract inhibited c-fos protein accumulation by 18.5% and 46.2% (p < 0.05), respectively, and p53 protein accumulation by 26.1% and 54.3% (p < 0.05), respectively. Similarly proliferating cell nuclear antigen staining, a marker of cell proliferation was induced (73.7%) in psoralen plus ultraviolet A-treated skin. Oral administration of 0.4% or 0.8% standardized green tea extract 1 d after psoralen plus ultraviolet A treatment was effective in reducing psoralen plus ultraviolet A-induced inflammatory responses including erythema and edema formation. When standardized green tea extract was applied to EpiDerm, a reconstituted human skin equivalent, psoralen plus ultraviolet A-induced 8-methoxypsoralen-DNA adduct formation and p53 protein accumulation were inhibited. Topical application of 0.2 mg 8-methoxypsoralen per cm2 followed by exposure to ultraviolet A (2.5 J per cm2) resulted in delayed erythema formation in human subjects. Pretreatment of human skin with topical application of 0.2 mg standardized green tea extract per cm2 30 min prior to psoralen plus ultraviolet A treatment resulted in an almost complete abrogation of psoralen plus ultraviolet A-induced erythema. In summary, these data demonstrate that standardized green tea extract protects against psoralen plus ultraviolet A-induced phototoxicity by inhibiting DNA damage and diminishing the inflammatory effects of this modality.


Subject(s)
Dermatitis, Phototoxic/prevention & control , PUVA Therapy/adverse effects , Skin/drug effects , Tea , Animals , DNA Damage , Female , Humans , Mice , Mice, Hairless , Proliferating Cell Nuclear Antigen/analysis , Proto-Oncogene Proteins c-fos/analysis , Tumor Suppressor Protein p53/analysis
13.
Photochem Photobiol ; 70(4): 637-44, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10546558

ABSTRACT

In previous studies, we showed that green tea and black tea extracts and their major polyphenolic constituents protect against UVB light-induced carcinogenesis in murine skin. All of these studies required chronic administration of tea extracts or specific constituents either topically or orally. However, it is not known whether acute or subchronic administration of black tea extracts or constituents can ameliorate UVB-induced early effects in skin. In the present study, cultured keratinocytes and mouse and human skin were employed to assess the effect of both oral and topical administration of standardized black tea extract (SBTE) and its two major polyphenolic subfractions namely BTF1 and BTF2 against UVB-induced photodamage. In SKH-1 hairless mice, topical application of SBTE (0.2 mg/cm2) prior to UVB exposure (180 mJ/cm2) resulted in 40% reduced incidence and 64% reduced severity of erythema and 50% reduction in skinfold thickness by day 6 when compared to nontreated UVB-exposed animals. The SBTE was also effective in protecting against UVB-induced erythema in human volunteers. Administration of SBTE 5 min after UVB irradiation was similarly effective in reducing UVB-induced inflammation in both murine and human skin. The major polyphenolic subfractions, BTF1 and BTF2, were also effective in protecting in mouse skin. The SBTE subfractions inhibited UVB-induced tyrosine phosphorylation of epidermal growth factor receptor (EGFR). The UVB irradiation of human epidermoid carcinoma cells resulted in 3.3-fold induction of tyrosine phosphorylation of EGFR. Pretreatment with BTF1 and BTF2 reduced tyrosine phosphorylation of EGFR by 53% and 31%, respectively. The UVB-mediated enhanced expression of the early response genes, c-fos and c-jun in human epidermal keratinocytes was reduced in a dose-dependent manner by SBTE. Topical application of SBTE was also effective in reducing accumulation of c-fos and p53 proteins by 82% and 78%, respectively, in UVB-exposed mouse skin. These data provide evidence that constituents of black tea can abrogate UVB-induced erythema and associated early events in murine and human skin.


Subject(s)
Dermatitis, Phototoxic/prevention & control , Skin/drug effects , Skin/radiation effects , Tea/chemistry , Administration, Oral , Administration, Topical , Adult , Animals , Cell Line , ErbB Receptors/metabolism , ErbB Receptors/radiation effects , Female , Genes, fos/drug effects , Genes, fos/radiation effects , Genes, jun/drug effects , Genes, jun/radiation effects , Genes, p53/drug effects , Genes, p53/radiation effects , Humans , Mice , Mice, Hairless , Skin/injuries , Ultraviolet Rays/adverse effects
14.
Cutis ; 64(4): 237-9, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10544877

ABSTRACT

The diagnosis and management of porphyria cutanea tarda (PCT) is complicated when it occurs in the context of renal failure, chronic hemodialysis, and anemia. We report a case of a woman who presented with painful acral blisters and hyperpigmentation. Her medical history included systemic lupus erythematosus, chronic hepatitis C infection, and renal failure necessitating chronic hemodialysis with a baseline anemia. A highly elevated serum porphyrin level led to the diagnosis of PCT. Treatment with small repeated phlebotomies and concomitant administration of erythropoietin was effective in managing her PCT.


Subject(s)
Hepatitis C, Chronic/complications , Kidney Failure, Chronic/complications , Lupus Erythematosus, Systemic/complications , Porphyria Cutanea Tarda/etiology , Adult , Erythropoietin/therapeutic use , Female , Follow-Up Studies , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/therapy , Humans , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/therapy , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/therapy , Phlebotomy , Porphyria Cutanea Tarda/diagnosis , Porphyria Cutanea Tarda/therapy , Renal Dialysis , Risk Assessment
15.
Biochem Biophys Res Commun ; 254(1): 49-53, 1999 Jan 08.
Article in English | MEDLINE | ID: mdl-9920731

ABSTRACT

EpiDerm (MatTek Co., MA) is a reconstituted human skin equivalent which exhibits morphological and growth characteristics similar to human skin. This model has previously been utilized to evaluate the cytotoxicity and irritant potential of various cosmetic and household products. In this study, we show for the first time that EpiDerm can be used successfully to evaluate the genotoxicity of different types of known carcinogenic agents such as benzo[a]pyrene (BaP), ultraviolet B radiation (UVB), ultraviolet A radiation (UVA), and psoralen-ultraviolet A radiation (PUVA) at the molecular level. The topical application of 50 microg/cm2 BaP to EpiDerm resulted in the accumulation of BaP-DNA adducts and c-fos and p53 proteins as evidenced by immunohistochemical localization. Similarly, exposure to UVB (50 mJ/cm2) and UVA (2.5 J/cm2) enhanced the epidermal expression of c-fos and p53 proteins in the human skin equivalent. PUVA treatment of EpiDerm, however, resulted in the formation of both DNA-8-MOP adducts and augmented expression of c-fos and p53 proteins. Most of these changes reached a peak 8 h after the treatments except in the case of UVA where maximum changes in the expression of c-fos and p53 proteins were observed 24 h after treatment. These results are similar to those previously reported in human and murine skin following exposure to BaP, UVB, UVA, or PUVA indicating that human skin equivalents can be used as a convenient and cost-effective alternative to animal testing for assessing the genotoxicity and mechanism of action of mutagens/carcinogens in human skin.


Subject(s)
Culture Techniques , Skin Neoplasms/pathology , Skin/pathology , Humans , Proto-Oncogene Proteins c-fos/analysis , Skin/metabolism , Skin/physiopathology , Tumor Suppressor Protein p53/analysis
18.
J Invest Dermatol ; 110(2): 190-2, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9457922
20.
Hum Genet ; 99(1): 126-9, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9003509

ABSTRACT

The porphyrias are disorders that result from the inherited or acquired dysregulation of one of the eight enzymes in the heme biosynthetic pathway. Variegate porphyria (VP) is characterized by deficiencies in protoporphyrinogen oxidase (PPO) and has recently been genetically linked (Z = 6.62) to the PPO gene on chromosome 1q21. In this study, we have identified two sequence variants in the PPO gene in a family with VP. The first is a neutral polymorphism at the -47 position of intron 2; this polymorphism is present in the general population and is unlikely to underlie the VP phenotype. The second is a mutation in the PPO gene in a patient with VP; the mutation consists of an apparently de novo 2-bp insertion in exon 3 of PPO and results in a frameshift and downstream premature termination codon. These data establish that a frameshift mutation in PPO is the underlying mutation in this patient with VP and explain the sporadic occurrence of the phenotype in this family.


Subject(s)
Chromosomes, Human, Pair 1 , DNA Transposable Elements , Oxidoreductases Acting on CH-CH Group Donors , Oxidoreductases/genetics , Porphyria Cutanea Tarda/genetics , Porphyrias, Hepatic/enzymology , Porphyrias, Hepatic/genetics , Adult , Amino Acid Sequence , Base Sequence , Chromosome Mapping , DNA Primers , Exons , Female , Flavoproteins , Humans , Male , Mitochondrial Proteins , Molecular Sequence Data , Nuclear Family , Pedigree , Polymerase Chain Reaction , Polymorphism, Genetic , Porphobilinogen/blood , Porphyria Cutanea Tarda/enzymology , Porphyrias, Hepatic/physiopathology , Porphyrins/metabolism , Protoporphyrinogen Oxidase
SELECTION OF CITATIONS
SEARCH DETAIL
...